ERBB2 and breast carcinoma: The efficacy of trastuzumab, an anti-HER2 monoclonal antibody that binds the HER2 extracellular domain preventing receptor dimerization, is well-defined both in metastatic and early HER2+ breast cancer (Hudis 2007).